Horizon Finance (HRZN) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Portfolio grew 6% in Q3 2024 to $684 million, with nine new loans totaling $93.1 million funded and a committed backlog of $190 million.
Net investment income for Q3 2024 was $11.8 million ($0.32 per share), down from $17.4 million ($0.53 per share) year-over-year.
Net asset value per share was $9.06 at September 30, 2024, down from $10.41 a year ago and $9.71 at December 31, 2023.
Regular monthly distributions of $0.11 per share declared through March 2025, supported by undistributed spillover income.
Strategic partnership between Monroe Capital and Wendel Group announced, expected to provide additional capital and scale, closing in Q1 2025.
Financial highlights
Total investment income for Q3 2024 was $24.6 million, down from $29.1 million year-over-year.
Net realized losses on investments were $33.9 million for Q3 and $31.4 million for the nine months, primarily due to one debt investment settlement.
Net unrealized appreciation for the nine months was $0.9 million, compared to $24.4 million in unrealized depreciation last year.
Dollar-weighted annualized yield on debt investments was 15.8% for the nine months, and 15.9% for Q3.
Undistributed spillover income stood at $1.27 per share at quarter end.
Outlook and guidance
Management expects continued portfolio growth in Q4 2024, supported by a robust pipeline and committed backlog.
Anticipates NII will cover distributions over time, with incentive fees expected to return to full accrual by end of 2025.
Board declared monthly distributions of $0.11 per share for January, February, and March 2025.
Company believes current cash, operations, and credit facilities will be sufficient for at least the next 12 months.
Focus remains on secured debt investments in technology, life science, healthcare information and services, and sustainability sectors.
Latest events from Horizon Finance
- Supplemental distributions proposed to enhance shareholder value amid merger approval process.HRZN
Proxy Filing11 Mar 2026 - Portfolio growth resumed in Q4, with strong yields and a transformative merger ahead.HRZN
Q4 20254 Mar 2026 - Merger creates a $446M NAV BDC, delivering a 33% NAV premium and scale benefits.HRZN
Q2 20253 Feb 2026 - NII and NAV fell, but 15.9% yield and strong liquidity support H2 2024 growth outlook.HRZN
Q2 20242 Feb 2026 - NII covered distributions in 2024, but NAV fell; strong yield and liquidity support 2025 growth.HRZN
Q4 202425 Dec 2025 - Vote sought on new investment management agreement; Board recommends approval for continuity.HRZN
Proxy Filing1 Dec 2025 - Shareholders will vote on director elections and auditor ratification, with robust governance in place.HRZN
Proxy Filing1 Dec 2025 - Shareholders to vote on a new investment management agreement after adviser's change in control.HRZN
Proxy Filing1 Dec 2025 - Vote on a new investment management agreement is urged following a change in adviser control.HRZN
Proxy Filing1 Dec 2025